Double-lumen central venous port catheters: simultaneous application for chemotherapy and parenteral nutrition in cancer patients.
OBJECTIVE
This study was designed to evaluate the clinical benefit of low-profile double-lumen port catheters in patients receiving simultaneous chemotherapy and parenteral nutrition (PN). Potential advantages, complications, and the durations of simultaneous and single use of the catheter were assessed.


METHODS
At a university teaching hospital, 10 patients received a double-lumen port catheter (5 men, 5 women; mean age 61.5 ± 12 years). All port implantations were performed under ultrasonographic and fluoroscopic guidance in the radiologic interventional suite. Procedure-related immediate, early, and late complications were recorded until removal of the device, patient's death, or completion of follow-up period. Application times and durations for chemotherapy or PN were determined.


RESULTS
No immediate complications were observed. First use of the port system for chemotherapy was within 12 days (± 25 days, range 0-84 days) and within 17 hours (± 22 hours, range 0-72 hours) for PN on average. During the application of PN, no delay or interruption of chemotherapy was observed. The port catheter was used for the simultaneous application of chemotherapy and PN for a total of 1,216 hours. One port catheter was removed after 30 days due to suspected port infection.


CONCLUSIONS
Central venous double-lumen port systems as a therapeutic option in patients requiring chemotherapy and PN can increase safety during those simultaneous applications, while offering improved patient comfort.
Teichgräber
Ulf K M
UK
Department of Radiology, Charité University Medicine, Berlin, Germany. ulf.teichgraeber@charite.de
Nagel
Sebastian N
SN
Kausche
Stephan
S
Streitparth
Florian
F
Cho
Chie Hee
CH
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D055499:Catheter-Related Infections / Q000209:etiology; D002405:Catheterization, Central Venous / Q000009:adverse effects / Q000295:instrumentation*; D002408:Catheters, Indwelling / Q000009:adverse effects; D020878:Device Removal; D004867:Equipment Design; D005260:Female; D005471:Fluoroscopy; D005858:Germany; D006785:Hospitals, University; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D010288:Parenteral Nutrition / Q000009:adverse effects; D015641:Radiography, Interventional; D013997:Time Factors; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
D000970:Antineoplastic Agents